non-squamous and non-small cell lung cancer, pleural mesothelioma
Conditions
Interventions
None listed
Sponsors
National center for global health and medicine
Department of Medical oncology, Funabashi Municipal Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Histologically or cytologically confirmed non-squamous and non-small cell lung cancer and malignant pleural mesothelioma 2) Stage IIIB without any indication for radiotherapy or Stage IV or recurrent disease after surgery or radiotherapy 3) Treated with pemetrexed including regimen 4) ECOG PS 0-1 5) 20 years old or older 6) With or without measurable lesion 7) Adequate organ function evaluated within 14 days before enrollment 8) Life expectancy more than 12 weeks 9) Written informed consent
Exclusion criteria
Exclusion criteria: 1) Treated with concurrent radiotherapy 2) Inappropriate for administration of pemetrexed a) a history of serious drug hypersensitivity b) severe myelosuppression, renal or hepatic dysfunction c) contraindicated for the use of pemetrexed d) severe comorbid disease e) administration of systemic antimicrobial agents f) continuous drainage for pleural effusion, ascites or cardiac effusion g) brain metastasis with any symptoms h) administration of systemic steroid i) pregnancy, lactation or intention to pregnancy j) judged to have difficulty in participation in this study because of psychosis or neurologic disease k) judged to be inadequate for this study by doctors
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse effects during 2 cycles of pemetrexed including chemotherapy | — |
Secondary
| Measure | Time frame |
|---|---|
| Response rate by RECIST criteria Progression free survival | — |
Countries
Japan
Contacts
Public ContactYuichiro Takeda
National center for global health and medicine Department of Respiratory Medicine
Outcome results
None listed